Abstract
A subunit antigenoid vaccine, Ac NFU1 (S-) MRC 5, was used in patients who had had a clinical episode of herpes genitalis. The rate of recurrence was compared with that in unvaccinated patients to determine the efficacy of vaccination in preventing recurrence and spread of the virus in the community. Seven of 22 (31%) vaccinated patients had eight recurrences after the initial clinical episode; in contrast there were 51 recurrences in 17 of 20 (85%) unvaccinated patients. Although further studies are needed, the results indicate that the vaccine may prevent recurrent episodes of herpes genitalis and thereby reduce the dissemination of this virus in the population.
| Original language | English |
|---|---|
| Pages (from-to) | 311-313 |
| Number of pages | 3 |
| Journal | British Journal of Venereal Diseases |
| Volume | 59 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 1 Oct 1983 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- vaccine
- NFU1(S) MRC5
- prevention
- herpes
- genitalis
ASJC Scopus subject areas
- General Medicine
- General Health Professions
- General Immunology and Microbiology
Fingerprint
Dive into the research topics of 'Efficacy of vaccine NFU1 (S-) MRC5 given after an initial clinical episode in the prevention of herpes genitalis'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver